Teva Pharma Q3 Beats Market, Lifts FY24 Outlook
Teva Pharma Q3 Beats Market, Lifts FY24 Outlook; Stock Up
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) Wednesday reported a loss in its third quarter, compared to prior year's profit, despite higher revenues. However, adjusted earnings and top line beat market estimates, and the firm lifted its fiscal 2024 forecast.
JERUSALEM (Reuters) - Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in ...
QRG Capital Management Inc. cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 1.6% during the third quarter, according to the company in its most recent ...
Teva Pharmaceutical Industries Limited ( (TEVA) ) has released its Q3 earnings. Here is a breakdown of the information Teva Pharmaceutical ...
Teva Pharmaceutical Industries Ltd (TEVA) reports a 15% revenue increase and raises 2024 guidance, despite facing legal and market challenges.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) will be announcing its earnings results before the market opens ...
Teva Pharmaceutical Industries’ shares were up 4% at 7,323 shekels today reported results for the quarter ended September 30, 2024.
While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some ...
Teva Pharmaceutical Industries Ltd. has been fined nearly €463 million ($503 million) by the European Union’s antitrust ...
Data from a phase 3 trial of Teva Pharmaceutical Industries' (NYSE:TEVA) TEV-'749 indicated that the long-acting, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback